We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) is a biotechnology company specializing in clinical ... read more Featured Products: More products

Download Mobile App





SNIBE Brings Latest Innovations in Immunoassay, Clinical Biochemistry and Molecular Diagnostics to Medlab Middle East 2023

By LabMedica International staff writers
Posted on 09 Feb 2023

SNIBE (Shenzhen, China) is bringing its latest innovations, including new members from its product lines in immunoassay, clinical biochemistry and molecular diagnostics to Medlab Middle East 2023. More...

At Medlab Middle East 2023, SNIBE is showcasing Biolumi CX8, the new lab booster that combines one of the fastest immunoassay system MAGLUMI X8, and the biochemical system Biossays C8, with ultra-high throughput in a very small footprint. Moreover, it can also be customized according to specific needs, supporting up to four connected instruments, and covering the requirements of different laboratories. SNIBE is also showcasing the MAGLUMI X6 flexible CLIA solution that is designed for medium/high-volume laboratories. The MAGLUMI X6 offers flexible configuration modules and features new generation hydraulic TIP pipetting technology. It has a high speed of 450 tests/hour and is suitable for 155 chemiluminescence immunoreagents.

In addition, SNIBE is highlighting the Molecision S6 automated, integrated digital PCR system that provides a full-platform solution for research/in vitro diagnostics. Molecision S6 uses a cutting-edge cartridge that provides uniform droplets and prevents contamination, maximizing operation productivity and cost efficiency. Light oil is pre-filled in the cartridge so that the droplets can be sunk under the light oil to ensure a fully enclosed condition, achieving a sensitivity of 0.002%. Its highly integrated design and optimized system make it space-saving and easy to use. Alongside the Molecision S6, SNIBE is highlighting the Molecision MP-32 and MP-96 fully-auto nucleic acid purification systems that adopt a high-performance magnetic extraction method, thereby maximizing the recovery rate and consistency of results.

Related Links:
SNIBE


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.